ClinicalTrials.gov 临床试验·· 5 天前AI 评分22
克唑替尼用于ROS1基因改变癌症的II期MATCH试验
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
AI 导读
II期MATCH试验评估克唑替尼在携带ROS1易位的癌症患者中的疗效。克唑替尼可阻断ROS1蛋白,研究者希望观察其能否使这类肿瘤缩小或停止生长。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov